


Stereochemistry abstracts

Tatsuo Yajima,* Takao Horikawa, Nobuhiro Takeda, Eri Takemura, Hiroaki Hattori, Yuichi Shimazaki, Tadashi Shiraiwa

Tetrahedron: Asymmetry 19 (2008) 1285




De = 98% [NMR]
 $[\alpha]_D^{25} = -38.3$ (*c* 2, 5 mol/dm³ HCl)
 Absolute configuration: (2*R*,3*S*)

C₆H₁₃O₂N₁
 (2*R*,3*S*)-2-Amino-3-methylpentanoic acid

Tatsuo Yajima,* Takao Horikawa, Nobuhiro Takeda, Eri Takemura, Hiroaki Hattori, Yuichi Shimazaki, Tadashi Shiraiwa

Tetrahedron: Asymmetry 19 (2008) 1285




De = 98% [NMR]
 $[\alpha]_D^{25} = -21.5$ (*c* 2, C₂H₅OH)
 Absolute configuration: (2*R*,3*S*)

C₈H₁₅O₃N₁
 (2*R*,3*S*)-*N*-Acetyl-2-amino-3-methylpentanoic acid

Tatsuo Yajima,* Takao Horikawa, Nobuhiro Takeda, Eri Takemura, Hiroaki Hattori, Yuichi Shimazaki, Tadashi Shiraiwa

Tetrahedron: Asymmetry 19 (2008) 1285




De = 98% [NMR]
 $[\alpha]_D^{25} = -23.0$ (*c* 1, CH₃OH)
 Absolute configuration: (2*R*,3*S*)

C₈H₁₈O₃N₂
 Ammonium (2*R*,3*S*)-*N*-acetyl-2-amino-3-methylpentanoate


Gang Liu, Jie Meng, Chen-Guo Feng, Pei-Qiang Huang*

Tetrahedron: Asymmetry 19 (2008) 1297




$[\alpha]_D^{20} = -23.8$ (*c* 1.0, CH₃OH)
 Source of chirality: (S)-glutamic acid
 Absolute configuration: (S)

C₁₃H₁₉NO₄
 (S)-*N*-(4-Methoxybenzyl)-2,5-dihydroxypentanamide




$[\alpha]_D^{20} = +44.0$ (*c* 1.0, CHCl₃)
Source of chirality: (S)-glutamic acid
Absolute configuration: (3S,6S)

C₁₈H₂₃NO₄
(3S,6S)-1-(4-Methoxybenzyl)-6-allyl-2-oxopiperidin-3-yl acetate




$[\alpha]_D^{20} = -73.9$ (*c* 1.1, CHCl₃)
Source of chirality: (S)-glutamic acid
Absolute configuration: (3S,6S)

C₁₆H₂₃NO₂
(3S,6S)-1-(4-Methoxybenzyl)-6-allylpiperidin-3-ol




$[\alpha]_D^{20} = -10.2$ (*c* 1.0, EtOH)
Source of chirality: (S)-glutamic acid
Absolute configuration: (2R,5S)

C₈H₁₇NO·HCl
(-)-(2R,5S)-epi-Pseudoconhydrine hydrochloride salt




$[\alpha]_D^{20} = -65.4$ (*c* 1.0, CHCl₃)
Source of chirality: (S)-glutamic acid
Absolute configuration: (3S,6S)

C₂₆H₃₁NO₅
(3S,6S)-1-(4-Methoxybenzyl)-6-(2-oxo-2-phenylethyl)-3-(tetrahydro-2H-pyran-2-yloxy)piperidin-2-one




$[\alpha]_D^{20} = -10.6$ (*c* 1.1, CHCl₃)
Source of chirality: (S)-glutamic acid
Absolute configuration: (3S,6S)

C₂₁H₂₃NO₄
(3S,6S)-1-(4-Methoxybenzyl)-3-hydroxy-6-(2-oxo-2-phenylethyl)piperidin-2-one




$[\alpha]_D^{20} = -59.3$ (*c* 1.0, CHCl₃)
Source of chirality: (S)-glutamic acid
Absolute configuration: (3S,6S)

C₂₁H₂₇NO₃
(3S,6S)-1-(4-Methoxybenzyl)-6-((S)-2-hydroxy-2-phenylethyl)piperidin-3-ol




$[\alpha]_D^{20} = -62.4$ (*c* 0.8, CHCl₃)
Source of chirality: (S)-glutamic acid
Absolute configuration: (2S,5S,2'S)

C₁₈H₂₇NO₄
(2S,5S)-tert-Butyl 5-hydroxy-2-((S)-2-hydroxy-2-phenylethyl)piperidine-1-carboxylate




$[\alpha]_D^{20} = -53.4$ (*c* 0.5, MeOH)
Source of chirality: (S)-glutamic acid
Absolute configuration: (3S,6S,2'S)

C₁₄H₂₁NO₂
(3S,6S)-6-((S)-2-Hydroxy-2-phenylethyl)-1-methylpiperidin-3-ol




$[\alpha]_D^{20} = +51.0$ (*c* 1.0, CHCl₃)
Source of chirality: (S)-glutamic acid
Absolute configuration: (3S,6S)

C₁₇H₂₁NO₅
(3S,6S)-1-(4-Methoxybenzyl)-2-oxo-6-(2-oxoethyl)piperidin-3-yl acetate




$[\alpha]_D^{20} = +6.9$ (*c* 1.4, CHCl₃)
Source of chirality: (S)-glutamic acid
Absolute configuration: (3S,6S)

C₂₃H₂₅NO₅
(3S,6S)-1-(4-Methoxybenzyl)-6-(2-oxo-2-phenylethyl)-2-oxopiperidin-3-yl acetate




Ee = 100%
 $[\alpha]_D^{25} = -25$ (*c* 0.13, CH₂Cl₂)
Source of chirality: chiral starting material
Absolute configuration: (R,R)

C₁₃H₁₇F₃N₂O₂S
N-(1R,2R)-(2-Aminocyclohexyl)-2-(trifluoromethyl)benzenesulfonamide





Ee = 100%
 $[\alpha]_D^{25} = -34$ (*c* 0.52, CH₂Cl₂)
Source of chirality: chiral starting material
Absolute configuration: (R,R)

C₁₃H₁₇F₃N₂O₂S
N-((1R,2R)-3-trifluoromethyl-2-(trifluoromethyl)cyclohexyl)-2-(trifluoromethyl)benzenesulfonamide

 $Ee = 100\%$ $[\alpha]_D^{25} = -57$ (*c* 0.26, CH_2Cl_2)



Source of chirality: chiral starting material

Absolute configuration: (R,R)

*N*-(1*R*,2*R*)-(2-Aminocyclohexyl)-4-(trifluoromethyl)benzenesulfonamide $Ee = 100\%$ $[\alpha]_D^{25} = -46$ (*c* 0.56, CH_2Cl_2)



Source of chirality: chiral starting material

Absolute configuration: (R,R)

*N*-(1*R*,2*R*)-(2-Aminocyclohexyl)-2,3,4-(trifluoro)benzenesulfonamide $Ee = 100\%$ $[\alpha]_D^{25} = -30$ (*c* 0.66, CH_2Cl_2)


Source of chirality: chiral starting material


Absolute configuration: (R,R)

*N*-(1*R*,2*R*)-(2-Aminocyclohexyl)-2-fluorobenzenesulfonamide $Ee = 100\%$ $[\alpha]_D^{25} = -64$ (*c* 0.52, CH_2Cl_2)

Source of chirality: chiral starting material


Absolute configuration: (R,R)

*N*-(1*R*,2*R*)-(2-Aminocyclohexyl)-3-fluorobenzenesulfonamide

 $Ee = 100\%$ $[\alpha]_D^{25} = -63$ (*c* 0.41 CH₂Cl₂)


Source of chirality: chiral starting material

Absolute configuration: (R,R)

*N*-(1*R*,2*R*)-(2-Aminocyclohexyl)-5-fluoro-2-methyl-benzenesulfonamide $Ee = 100\%$ $[\alpha]_D^{25} = -39$ (*c* 0.42 CH₂Cl₂)



Source of chirality: chiral starting material

Absolute configuration: (R,R)

*N*-(1*R*,2*R*)-(2-Aminocyclohexyl)-4-iodobenzenesulfonamide $Ee = 100\%$ $[\alpha]_D^{25} = -22$ (*c* 0.31, CH₂Cl₂)


Source of chirality: chiral starting material


Absolute configuration: (R,R)

*N*-(1*R*,2*R*)-(2-Aminocyclohexyl)-4-chlorobenzenesulfonamide $Ee = 100\%$ $[\alpha]_D^{25} = -29$ (*c* 0.11, CH₂Cl₂)



Source of chirality: chiral starting material

Absolute configuration: (R,R)


*N*-(1*R*,2*R*)-(2-Aminocyclohexyl)-2,5-dichlorobenzenesulfonamide




Ee = 100%
 $[\alpha]_D^{25} = -33$ (*c* 0.57, CH₂Cl₂)
 Source of chirality: chiral starting material
 Absolute configuration: (R,R)

N-(1*R*,2*R*)-(2-Aminocyclohexyl)-4-chloro-2-methoxybenzenesulfonamide*N*-(1*R*,2*R*)-(2-Aminocyclohexyl)-4-cyano-benzenesulfonamide*N*-(1*R*,2*R*)-(2-Aminocyclohexyl)-3-cyano-benzenesulfonamide

Ee = 100%
 $[\alpha]_D^{25} = -63$ (*c* 0.42 CH₂Cl₂)
 Source of chirality: chiral starting material
 Absolute configuration: (R,R)


4-Acetyl-*N*-(1*R*,2*R*)-(2-aminocyclohexyl)benzenesulfonamide

Ee = 100%
 $[\alpha]_D^{25} = -28$ (*c* 0.22, CH₂Cl₂)
 Source of chirality: chiral starting material
 Absolute configuration: (R,R)

 $Ee = 100\%$ $[\alpha]_D^{25} = -33$ (*c* 0.44, CH₂Cl₂)


Source of chirality: chiral starting material

Absolute configuration: (R,R)

 $C_{16}H_{26}N_2O_3S$ *N*-(1*R*,2*R*)-2-Aminocyclohexyl-4-butoxy-benzenesulfonamide $Ee = 100\%$ $[\alpha]_D^{25} = -15$ (*c* 0.81, CH₂Cl₂)


Source of chirality: chiral starting material

Absolute configuration: (R,R)

 $C_{14}H_{22}N_2O_4S$ *N*-(1*R*,2*R*)-(2-Aminocyclohexyl)-2,5-dimethoxy-benzenesulfonamide $Ee = 100\%$ $[\alpha]_D^{25} = -57$ (*c* 0.26 CH₂Cl₂)

Source of chirality: chiral starting material


Absolute configuration: (R,R)

 $C_{13}H_{20}N_2O_3S$ *N*-(1*R*,2*R*)-(2-Aminocyclohexyl)-4-methoxy-benzenesulfonamide $Ee = 100\%$ $[\alpha]_D^{25} = -85$ (*c* 1.0 CH₂Cl₂)

Source of chirality: chiral starting material

Absolute configuration: (R,R)

 $C_{13}H_{20}N_2O_3S$ *N*-(1*R*,2*R*)-(2-Aminocyclohexyl)-3-methoxy-benzenesulfonamide



(2S,6S)-Bicyclo[3.3.1]nonane-2,6-dione

[α]_D²¹ = +176.6 (c 0.5, CHCl₃)

Source of chirality: yeast kinetic resolution

Absolute configuration: (2S,6S)





(2S,6S)-Bicyclo[3.3.1]nona-2,6-diene

[α]_D²¹ = -121 (c 0.89, CHCl₃)

Source of chirality: enantiomerically pure ketone precursor

Absolute configuration: (2S,6S)





((2S,6S)-Bicyclo[3.3.1]nona-2,6-diene)2',4'-pentanedionato rhodium

[α]_D²¹ = -73 (c 0.51, CHCl₃)

Source of chirality: enantiomerically pure diene precursor

Absolute configuration: (2S,6S) (diene chirality)




(Bis-(S,S)-bicyclo[3.3.1]nona-2,6-diene)rhodium trifluoromethanesulfonate

[α]_D²¹ = -217 (c 0.29, CHCl₃)

Source of chirality: enantiomerically pure diene precursor


Absolute configuration: (2S,6S) (diene chirality)




$[\alpha]_D^{21} = -260$ (*c* 0.23, CHCl₃)

Source of chirality: enantiomerically pure diene
precursor

Absolute configuration: (2*S*,6*S*) (diene chirality)




(Bis-(*S,S*)-bicyclo[3.3.1]nona-2,6-diene)rhodium trifluoromethanesulfonate




Ee = 97% (Chiral HPLC)

$[\alpha]_D^{20} = -38.2$ (*c* 1.20, CHCl₃)

Source of chirality: enzymatic desymmetrization
Absolute configuration: (3*aR*,4*R*,6*S*,6*aS*)




tert-Butyl (3*aR*,4*R*,6*S*,6*aS*)-4-(acetoxymethyl)-6-(hydroxymethyl)-2,2-dimethylhydro-3*aH*-[1,3]dioxolo[4,5-*c*]pyrrole-5(4*H*)-carboxylate




Ee = 94%

$[\alpha]_D^{20} = -8.7$ (*c* 1.50, CHCl₃)

Source of chirality: enzymatic desymmetrization
Absolute configuration: (2*R*,3*R*,4*S*,5*S*)




tert-Butyl (2*R*,3*R*,4*S*,5*S*)-2-(acetoxymethyl)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidine-1-carboxylate




Ee = 97% (Chiral GC)

$[\alpha]_D^{20} = -10.9$ (*c* 1.60, CHCl₃)


Source of chirality: enzymatic desymmetrization
Absolute configuration: (2*S*,5*R*)




tert-Butyl (2*S*,5*R*)-2-(acetoxymethyl)-5-(hydroxymethyl)pyrrolidine-1-carboxylate



Ee ≥ 98% (Chiral HPLC)
 $[\alpha]_D^{20} = +12.9$ (c 1.40, MeOH)
 Source of chirality: enzymatic desymmetrization
 Absolute configuration: (2S,5R)




(2S,5R)-1-(*tert*-Butoxycarbonyl)-5-(methoxycarbonyl)pyrrolidine-2-carboxylic acid




Ee = 100%
 $[\alpha]_D^{20} = +217.5$ (c 0.50, CH₂Cl₂)
 Source of chirality: resolution
 Absolute configuration: (R)




(R)-(+)-N,N'-Bis(2,3-dichlorobenzylidene)-1,1'-binaphthyl-2,2'-diamine



Ee = 100%
 $[\alpha]_D^{20} = +140.5$ (c 0.50, CH₂Cl₂)
 Source of chirality: optical resolution
 Absolute configuration: (R)




(R)-(+)-N,N'-Bis(2,4-dichlorobenzylidene)-1,1'-binaphthyl-2,2'-diamine



Ee = 100%
 $[\alpha]_D^{20} = +117.7$ (c 0.50, CH₂Cl₂)
 Source of chirality: resolution
 Absolute configuration: (R)




(R)-(+)-N-(2,3-Dichlorobenzylidene)-1,1'-binaphthyl-2,2'-diamine




Ee = 100%
 $[\alpha]_D^{20} = +3.8$ (c 0.35, CH₂Cl₂)
 Source of chirality: resolution
 Absolute configuration: (R)

C₄₆H₃₈Cl₂N₂
(R)-(+)-N,N'-Bis(2-chlorobenzylidene)-3,3'-diphenyl-5,5',6,6',7,7',8,8'-octahydro-1,1'-binaphthyl-2,2'-diamine




C₆H₁₂O₃
Ethyl (R)-3-hydroxybutyrate

Ee = 94.5% by chiral GC with a CP-Chirasil-Dex-CB column
 $[\alpha]_D^{25} = -43.1$ (c 1.0, CHCl₃)
 Source of chirality: *Bacillus pumilus* Phe-C3 alcohol dehydrogenase
 Absolute configuration: (3R)




C₆H₁₁O₃Cl
Ethyl (S)-4-chloro-3-hydroxybutyrate

Ee = 95.9% by chiral GC with a CP-Chirasil-Dex-CB column
 $[\alpha]_D^{25} = -21.7$ (c 7.0, CHCl₃)
 Source of chirality: *Bacillus pumilus* Phe-C3 alcohol dehydrogenase
 Absolute configuration: (3S)



C₆H₁₁O₃Br
Ethyl (S)-4-bromo-3-hydroxybutyrate

Ee = 91.4% by chiral GC with a CP-Chirasil-Dex-CB column
 $[\alpha]_D^{25} = -10.9$ (c 1.0, CHCl₃)
 Source of chirality: *Bacillus pumilus* Phe-C3 alcohol dehydrogenase
 Absolute configuration: (3S)





Ethyl (S)-3-hydroxy-3-phenylpropionate

Ee = 95.7% by chiral HPLC with a Chiracel OB-H column
 $[\alpha]_D^{25} = -33.1$ (c 1.0, CHCl₃)

Source of chirality: *Bacillus pumilus* Phe-C3 alcohol dehydrogenase

Absolute configuration: (3S)




Ethyl (R)-4-cyano-3-hydroxybutyrate

Ee = 97.0% by chiral GC with a CP-Chirasil-Dex-CB column
 $[\alpha]_D^{25} = -32.1$ (c 1.0, CHCl₃)

Source of chirality: *Bacillus pumilus* Phe-C3 alcohol dehydrogenase

Absolute configuration: (3R)




Ethyl (R)-4,4,4-trifluoro-3-hydroxybutyrate

Ee = 90.2% by chiral GC with a CP-Chirasil-Dex-CB column
 $[\alpha]_D^{25} = +20.1$ (c 1.0, CHCl₃)

Source of chirality: *Bacillus pumilus* Phe-C3 alcohol dehydrogenase

Absolute configuration: (3R)




Ethyl (R)-2-hydroxy-propionate

Ee = 94.1% by chiral GC with a CP-Chirasil-Dex-CB column
 $[\alpha]_D^{25} = +14.3$ (c 1.0, CHCl₃)

Source of chirality: *Bacillus pumilus* Phe-C3 alcohol dehydrogenase


Absolute configuration: (2R)

 $C_{10}H_{12}O_3$ Ethyl (R)- α -hydroxybenzeneacetate

Ee = 96.6% by chiral HPLC with a Chiralcel OB-H column

 $[\alpha]_D^{25} = -99.3$ (c 1.0, CHCl₃)Source of chirality: *Bacillus pumilus* Phe-C3 alcohol dehydrogenase

Absolute configuration: (2R)


 $C_{12}H_{16}O_3$

Ethyl (R)-2-hydroxy-4-phenylbutyrate

Ee = 97.1% by chiral HPLC with a Chiralcel OB-H column

 $[\alpha]_D^{25} = -19.5$ (c 1.0, CHCl₃)Source of chirality: *Bacillus pumilus* Phe-C3 alcohol dehydrogenase

Absolute configuration: (2R)


 $C_{14}H_{17}NO_3$

(S)-2-((R)-2-Nitro-1-phenylethyl)cyclohexanone

Ee = 91%

 $[\alpha]_D^{20} = -26.1$ (c 1.0, CHCl₃)

Absolute configuration: (S,R)


 $C_{14}H_{15}Cl_2NO_3$

(S)-2-((R)-1-(2,4-Dichlorophenyl)-2-nitroethyl)cyclohexanone

Ee = 88%


 $[\alpha]_D^{20} = -43.9$ (c 1.0, CHCl₃)

Absolute configuration: (S,R)




$C_{14}H_{16}N_2O_5$
(*S*)-2-((*R*)-2-Nitro-1-(3-nitrophenyl)ethyl)cyclohexanone

Ee = 87%
 $[\alpha]_D^{20} = -23.7$ (*c* 1.0, CHCl₃)
 Absolute configuration: (*S,R*)




$C_{15}H_{19}NO_4$
(*S*)-2-((*R*)-1-(4-Methoxyphenyl)-2-nitroethyl)cyclohexanone

Ee = 84%
 $[\alpha]_D^{20} = -25.3$ (*c* 1.0, CHCl₃)
 Absolute configuration: (*S,R*)




$C_{14}H_{16}ClNO_3$
(*S*)-2-((*R*)-1-(2-Chlorophenyl)-2-nitroethyl)cyclohexanone

Ee = 89%
 $[\alpha]_D^{20} = -23.1$ (*c* 1.0, CHCl₃)
 Absolute configuration: (*S,R*)




$C_{14}H_{16}ClNO_3$
(*S*)-2-((*R*)-1-(4-Chlorophenyl)-2-nitroethyl)cyclohexanone

Ee = 93%
 $[\alpha]_D^{20} = -33.7$ (*c* 1.0, CHCl₃)
 Absolute configuration: (*S,R*)




(S)-2-((R)-1-(4-Methylphenyl)-2-nitroethyl)cyclohexanone

Ee = 85%
 $[\alpha]_D^{20} = -21.2$ (*c* 1.0, CHCl₃)
 Absolute configuration: (S,R)




(S)-2-((R)-1-(2-Bromophenyl)-2-nitroethyl)cyclohexanone

Ee = 87%
 $[\alpha]_D^{20} = -47.9$ (*c* 1.60, CHCl₃)
 Absolute configuration: (S,R)




(S)-2-((R)-1-(4-Bromophenyl)-2-nitroethyl)cyclohexanone

Ee = 89%
 $[\alpha]_D^{20} = -25.8$ (*c* 1.0, CHCl₃)
 Absolute configuration: (S,R)




(S)-2-((S)-1-(Furan-2-yl)-2-nitroethyl)cyclohexanone

Ee = 88%
 $[\alpha]_D^{20} = -13.3$ (*c* 1.0, CHCl₃)
 Absolute configuration: (S,S)




(S)-2-((R)-1-(Naphthalen-2-yl)-2-nitroethyl)cyclohexanone

Ee = 77%
 $[\alpha]_D^{20} = -28.5$ (c 1.0, CHCl₃)
 Absolute configuration: (S,R)




(R)-5-Nitro-4-phenylpentan-2-one

Ee = 40%
 $[\alpha]_D^{20} = -7.2$ (c 1.0, CHCl₃)
 Absolute configuration: (R)



Methyl (1R,2S,5S,αS)-2-[N-benzyl-N-(α-methylbenzyl)amino]-5-tris(phenylthio)methyl-cyclopentane-carboxylate

$[\alpha]_D^{23} = -81.9$ (c 1.0, CHCl₃)
 source of chirality: asymmetric synthesis
 absolute configuration: (1R,2S,5S,αS)




Methyl (1R,2S,5S,αS)-2-[N-benzyl-N-(α-methylbenzyl)amino]-5-methyl-cyclopentane-carboxylate

$[\alpha]_D^{20} = -50.4$ (c 1.1, CHCl₃)
 source of chirality: asymmetric synthesis
 absolute configuration: (1R,2S,5S,αS)

Elin Abraham, Stephen G. Davies*, Alexander J. Docherty, Kenneth B. Ling,
Paul M. Roberts, Angela J. Russell, James E. Thomson, Steven M. Toms

Tetrahedron: Asymmetry 19 (2008) 1356




$[\alpha]_D^{23} = +72.0$ (*c* 1.0, CHCl₃)
source of chirality: asymmetric synthesis
absolute configuration: (1*S*,2*R*,5*R*, α *R*)

Methyl (1*S*,2*R*,5*R*, α *R*)-2-[N-(3,4-dimethoxybenzyl)-N-(α -methylbenzyl)amino]-5-tris(phenylthio)methyl-cyclopentane-carboxylate

Elin Abraham, Stephen G. Davies*, Alexander J. Docherty, Kenneth B. Ling,
Paul M. Roberts, Angela J. Russell, James E. Thomson, Steven M. Toms

Tetrahedron: Asymmetry 19 (2008) 1356




$[\alpha]_D^{23} = +27.0$ (*c* 0.9, CHCl₃)
source of chirality: asymmetric synthesis
absolute configuration: (1*S*,2*R*,5*R*, α *R*)

Methyl (1*S*,2*R*,5*R*, α *R*)-2-[N-(3,4-dimethoxybenzyl)-N-(α -methylbenzyl)amino]-5-methyl-cyclopentane-carboxylate

Elin Abraham, Stephen G. Davies*, Alexander J. Docherty, Kenneth B. Ling,
Paul M. Roberts, Angela J. Russell, James E. Thomson, Steven M. Toms

Tetrahedron: Asymmetry 19 (2008) 1356




$[\alpha]_D^{20} = +126$ (*c* 1.0, CHCl₃)
source of chirality: asymmetric synthesis
absolute configuration: (1*S*,2*R*,5*R*, α *R*)

Methyl (1*S*,2*R*,5*R*, α *R*)-2-[N-(α -methylbenzyl)amino]-5-methyl-cyclopentane-carboxylate

Elin Abraham, Stephen G. Davies*, Alexander J. Docherty, Kenneth B. Ling,
Paul M. Roberts, Angela J. Russell, James E. Thomson, Steven M. Toms

Tetrahedron: Asymmetry 19 (2008) 1356




$[\alpha]_D^{20} = +29.8$ (*c* 1.0, CHCl₃)
source of chirality: asymmetric synthesis
absolute configuration: (1*R*,2*S*,5*S*)

C₁₀H₁₅F₃NO₃.TFA
Methyl (1*R*,2*S*,5*S*)-2-ammonio-5-methyl-cyclopentane-carboxylate trifluoroacetate

Elin Abraham, Stephen G. Davies*, Alexander J. Docherty, Kenneth B. Ling,
Paul M. Roberts, Angela J. Russell, James E. Thomson, Steven M. Toms

Tetrahedron: Asymmetry 19 (2008) 1356




$[\alpha]_D^{17} = +19.0$ (*c* 1.0, H₂O)
source of chirality: asymmetric synthesis
absolute configuration: (1*R*,2*S*,5*S*)

C₇H₁₃NO₂
(1*R*,2*S*,5*S*)-2-Amino-5-methyl-cyclopentane-carboxylic acid

Elin Abraham, Stephen G. Davies*, Alexander J. Docherty, Kenneth B. Ling,
Paul M. Roberts, Angela J. Russell, James E. Thomson, Steven M. Toms

Tetrahedron: Asymmetry 19 (2008) 1356




$[\alpha]_D^{17} = -30.0$ (*c* 1.0, CHCl₃)
source of chirality: asymmetric synthesis
absolute configuration: (1*S*,2*R*,5*R*)

C₁₀H₁₅F₃NO₃
Methyl (1*S*,2*R*,5*R*)-2-ammonio-5-methyl-cyclopentane-carboxylate trifluoroacetate

Elin Abraham, Stephen G. Davies*, Alexander J. Docherty, Kenneth B. Ling,
Paul M. Roberts, Angela J. Russell, James E. Thomson, Steven M. Toms

Tetrahedron: Asymmetry 19 (2008) 1356




$[\alpha]_D^{17} = -18.8$ (*c* 1.0, H₂O)
source of chirality: asymmetric synthesis
absolute configuration: (1*S*,2*R*,5*R*)

C₇H₁₃NO₂
(1*S*,2*R*,5*R*)-2-Amino-5-methyl-cyclopentane-carboxylic acid


Giordano Lesma, Tullio Pilati, Alessandro Sacchetti*, Alessandra Silvani

Tetrahedron: Asymmetry 19 (2008) 1363




$[\alpha]_D^{20} = +6.5$ (*c* 1, CHCl₃)
Source of asymmetry: (S)-1-phenyl-ethylamine
Absolute configuration: (1'S,1R,2R,4S,5S)

C₃₂H₃₄N₂O₅
(1*R*,2*R*,4*S*,5*S*)-3-Methyl-9-oxo-2,4-diphenyl-7-((S)-1-phenyl-ethyl)-3,7-diaza-bicyclo[3.3.1]nonane-1,5-dicarboxylic acid dimethyl ester




$[\alpha]_D^{20} = +4.9$ (*c* 1, CHCl₃)
Source of asymmetry: (S)-1-phenyl-ethylamine
Absolute configuration: (1'S,1R,2R,4S,5S)

(1*R*,2*R*,4*S*,5*S*)-3-Methyl-2,4-bis-(4-nitro-phenyl)-9-oxo-7-((S)-1-phenyl-ethyl)-3,7-diaza-bicyclo[3.3.1]nonane-1,5-dicarboxylic acid dimethyl ester




$[\alpha]_D^{20} = +12.9$ (*c* 1, CHCl₃)
Source of asymmetry: (S)-1-naphthalen-1-yl-ethylamine
Absolute configuration: (1'S,1R,2R,4S,5S)

(1*R*,2*R*,4*S*,5*S*)-3-Methyl-7-((S)-1-naphthalen-1-yl-ethyl)-2,4-bis-(4-nitro-phenyl)-9-oxo-3,7-diaza-bicyclo[3.3.1]nonane-1,5-dicarboxylic acid dimethyl ester




$[\alpha]_D^{20} = +8.0$ (*c* 1, CHCl₃)
Source of asymmetry: (R)-1-phenyl-ethylamine
Absolute configuration: (1'S,1R,2R,4S,5S)

(1*R*,2*S*,4*R*,5*S*)-3-Methyl-9-oxo-7-((S)-1-phenyl-ethyl)-2,4-di-pyridin-2-yl-3,7-diaza-bicyclo[3.3.1]nonane-1,5-dicarboxylic acid dimethyl ester




$[\alpha]_D^{23} = -130.2$ (*c* 1.01, CHCl₃)
Source of chirality: (S)-glutamic acid
Absolute configuration: (S)

C₂₇H₃₀BF₄N₃OSi
(S)-5-[Diphenyl(trimethylsilyloxy)methyl]-2-phenyl-6,7-dihydro-5*H*-pyrrolo[2,1-*c*][1,2,4]triazol-2-ium tetrafluoroborate




$[\alpha]_D^{23} = -137.5$ (*c* 1.01, CHCl₃)
Source of chirality: (S)-glutamic acid
Absolute configuration: (S)

C₃₀H₃₆BF₄N₃OSi
(S)-5-[(tert-Butyldimethylsilyloxy)diphenylmethyl]-2-phenyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium tetrafluoroborate




$[\alpha]_D^{23} = -46.3$ (*c* 1.01, CHCl₃)
Source of chirality: (S)-glutamic acid
Absolute configuration: (S)

C₁₇H₂₆BF₄N₃OSi
(S)-2-Phenyl-5-[2-(trimethylsilyloxy)propan-2-yl]-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium tetrafluoroborate




$[\alpha]_D^{23} = +14.5$ (*c* 1.01, CHCl₃)
Source of chirality: (S)-glutamic acid
Absolute configuration: (S)

C₂₄H₂₂BF₄N₃OSi
(S)-5-Benzhydryl-2-phenyl-6,7-dihydro-5H-pyrrolo[2,1-c][1,2,4]triazol-2-ium tetrafluoroborate



De >99%
 $[\alpha]_D = -36.6$ (*c* 0.18, C₆Cl₃)
Source of chirality: asymmetric synthesis
Absolute configuration: (2S,3S,4R)


C₁₂H₁₆F₆O₉S₂
Methyl 5-((2S,3S,4R)-3,4-bis(trifluoromethylsulfonyloxy)tetrahydrofuran-2-yl)pentanoate



De >99%

 $[\alpha]_D = +31.3$ (*c* 0.15, CHCl_3)

Source of chirality: asymmetric synthesis

Absolute configuration: (2*S*,3*S*,4*R*) $\text{C}_{10}\text{H}_{16}\text{N}_6\text{O}_3$ Methyl 5-((2*S*,3*S*,4*R*)-3,4-diazidotetrahydrofuran-2-yl)pentanoate


De >99%

 $[\alpha]_D = +57.2$ (*c* 0.10, 1 M NaOH)


Source of chirality: asymmetric synthesis


Absolute configuration: (2*S*,3*S*,4*R*) $\text{C}_{11}\text{H}_{16}\text{N}_2\text{O}_4$

(+) -Oxybiotin

 $[\alpha]_D^{25} = +37.3$ (*c* 0.88, CHCl_3)Source of chirality: (*S*)-(+) -but-3-en-2-olAbsolute configuration: (2*S*) $\text{C}_8\text{H}_{12}\text{O}_3$ 2(*S*)-But-3-en-2-yl acetoacetate $[\alpha]_D^{25} = +59.7$ (*c* 0.52, CHCl_3)


Source of chirality: the precursor

Absolute configuration: (2*S*) $\text{C}_{12}\text{H}_{13}\text{ClN}_2\text{O}_2$ N-[1-Chloro-2-oxo-2(2(*S*)-but-3-enyloxy)acetylidene]-N'-phenylhydrazine




2-Phenyl-3a(S)-4(S)-methyl-6-oxo-3,3a,4,5-tetrahydro-furo[3,4-c]pyrazole

$[\alpha]_D^{25} = +66.1$ (*c* 0.77, CHCl₃)
Source of chirality: the precursor
Absolute configuration: 3a(S),4(S)




2-Phenyl-3a(R)-4(S)-methyl-6-oxo-3,3a,4,5-tetrahydro-furo[3,4-c]pyrazole


$[\alpha]_D^{25} = -21.4$ (*c* 0.59, CHCl₃)
Source of chirality: the precursor
Absolute configuration: 3a(R),4(S)

Methyl 2,3,4,9,10,11-hexa-O-benzyl-7,8-dideoxy-7,8-didehydro-12,13-O-isopropylidene- α -D-glucopyranoside

$[\alpha]_D = +6.9$ (*c* 1.0, CHCl₃)
Source of chirality: chiral pool
Absolute configuration: (1S,2R,3S,4R,5S,9S,10R,11R,12R)

Methyl 2,3,4,9,10,11-hepta-O-benzyl-7,8-dideoxy-7,8-didehydro-12,13-O-isopropylidene- α -D-glycero-D-ido-D-glucopyranoside


$[\alpha]_D = +17.9$ (*c* 1.0, CHCl₃)
Source of chirality: chiral pool
Absolute configuration: (1S,2R,3S,4R,5R,6S,9S,10R,11R,12R)




$[\alpha]_D = +29.1$ (*c* 1.0, CHCl₃)
Source of chirality: chiral pool
Absolute configuration: (1*S*,2*R*,3*S*,4*R*,5*R*,6*R*,9*S*,10*R*,11*R*,12*R*)




Methyl 2,3,4,9,10,11-penta-O-benzyl-7,8-dideoxy-7,8-didehydro-12,13-O-isopropylidene- α -D-glycero-D-gulo-D-gluco-tridec-7(*E*)-eno-1,5-pyranoside




$[\alpha]_D = +9.3$ (*c* 1.0, CHCl₃)
Source of chirality: chiral pool
Absolute configuration: (1*S*,2*R*,3*S*,4*R*,5*R*,6*R*,9*S*,10*R*,11*R*,12*R*)




Methyl 2,3,4,6,9,10,11-hepta-O-benzyl-7,8-dideoxy-7,8-didehydro-12,13-O-isopropylidene- α -D-glycero-D-gulo-D-gluco-tridec-7(*E*)-eno-1,5-pyranoside




$[\alpha]_D = +44.7$ (*c* 1.0, CHCl₃)
Source of chirality: chiral pool
Absolute configuration: (1*S*,2*R*,3*S*,4*R*,5*R*,6*S*,9*S*,10*R*,11*R*,12*R*)




Methyl 2,3,4,6,9,10,11-hepta-O-benzyl-7,8-dideoxy-7,8-didehydro-12,13-O-isopropylidene- α -D-glycero-D-ido-D-gluco-trideca-7(*E*)-eno-1,5-pyranoside



$[\alpha]_D = -3.0$ (*c* 1.0, CHCl₃)
Source of chirality: chiral pool
Absolute configuration: (1*S*,2*R*,3*S*,4*R*,5*R*,6*R*,7*R*,8*S*,9*R*,10*S*,11*R*,12*R*)





Methyl 2,3,4,6,9,10,11-hepta-O-benzyl-7,8-di-O-benzoyl-12,13-O-isopropylidene- α -D-arabino-D-gulo-D-gluco-trideca-1,5-pyranoside

 $[\alpha]_D = +37.4$ (c 1.0, CHCl₃)



Source of chirality: chiral pool

Absolute configuration: (1S,2R,3S,4R,5R,6R,7S,8R,9R,10S,11R,12R)

Methyl 2,3,4,6,9,10,11-hepta-O-benzyl-7,8-di-O-benzoyl-12,13-O-isopropylidene- α -D-arabino-D-gluco-D-gluco-trideca-1,5-pyranoside $[\alpha]_D = +11.1$ (c 1.0, CHCl₃)



Source of chirality: chiral pool

Absolute configuration: (1S,2R,3S,4R,5R,6S,7S,8R,9R,10S,11R,12R)

Methyl 2,3,4,6,9,10,11-hepta-O-benzyl-12,13-O-isopropylidene- α -D-arabino-D-ido-D-gluco-trideca-1,5-pyranoside $[\alpha]_D = -4.7$ (c 1.0, CHCl₃)

Source of chirality: chiral pool

Absolute configuration: (1S,2R,3S,4R,5R,8S,9S,10R,11R,12R)


Methyl 8,11-anhydro-2,3,4,9,10-penta-O-benzyl-6,7-dideoxy-6,7-didehydro-12,13-O-isopropylidene- α -D-glycero-D-gulo-D-gluco-tridec-6(E)-eno-1,5-pyranoside $[\alpha]_D^{25} = -179.2$ (c 1.3, CHCl₃)

Source of chirality: (R)-carvone


Absolute configuration: (10S)




(10S)-10-isopropenyl-7-methylspiro[4.5]deca-2,7-dien-6-one




$[\alpha]_D^{25} = +7.8$ (*c* 1.8, CHCl₃)
Source of chirality: (*R*)-carvone
Absolute configuration: (10*S*)

*C*₁₇H₂₂O(10*S*)-6-Allyl-10-isopropenyl-7-methylspiro[4.5]deca-2,6-dien-8-one

$[\alpha]_D^{20} = +13.2$ (*c* 4.8, CHCl₃)
Source of chirality: (*R*)-carvone
Absolute configuration: (6*R*,7*S*,10*S*)


*C*₂₀H₂₈O(6*R*,7*S*,10*S*)-6,7-Bis-allyl-10-isopropenyl-7-methylspiro[4.5]dec-2-en-8-one

$[\alpha]_D^{24} = +3.7$ (*c* 1.9, CHCl₃)
Source of chirality: (*R*)-carvone
Absolute configuration: (6*R*,7*R*,10*S*)

*C*₂₀H₂₈O(6*R*,7*R*,10*S*)-6,7-Bis-allyl-10-isopropenyl-7-methylspiro[4.5]dec-2-en-8-one


$[\alpha]_D^{27} = -3.3$ (*c* 0.6, CHCl₃)
Source of chirality: (*R*)-carvone
Absolute configuration: (1*R*,4*S*,6*R*)

*C*₁₈H₂₄O(1*R*,4*S*,6*R*)-4-Isopropenyl-1-methylbicyclo[4.4.0]decane-spiro[5.1]cyclopenta-8,3-dien-2-one




$C_{18}H_{24}O$
(*S*,*S*,*R*)-(−)-4-isopropenyl-1-methylbicyclo[4.4.0]decane-spiro[5.1]cyclopenta-8,3-dien-2-one

$[\alpha]_D^{21} = +25.7$ (*c* 2.5, CHCl₃)
Source of chirality: (*R*)-carvone
Absolute configuration: (*1S,4S,6R*)




$C_8H_{10}O$
(*R*)-(+)-1-Phenylethanol

Ee = 77.7%
 $[\alpha]_D^{24} = +38.5$ (*c* 1.12, CH₂Cl₂)
Source of chirality: asymmetric hydrogenation
Absolute configuration: (*R*)



$C_9H_{12}O$
(*R*)-(+)-1-Phenylpropanol

Ee = 78.0%
 $[\alpha]_D^{24} = +22.6$ (*c* 1.23, C₂H₅OH)
Source of chirality: asymmetric hydrogenation
Absolute configuration: (*R*)



C_8H_9OF
(*R*)-(+)-1-(2'-Fluorophenyl)ethanol


Ee = 44.3%
 $[\alpha]_D^{24} = +21.7$ (*c* 1.36, CHCl₃)
Source of chirality: asymmetric hydrogenation
Absolute configuration: (*R*)

Ee = 43.7%

 $[\alpha]_D^{24} = +29.3$ (*c* 1.24, CHCl₃)

Source of chirality: asymmetric hydrogenation

Absolute configuration: (R)

C₈H₉OBr


(R)-(+)-1-(2'-Bromophenyl)ethanol

Ee = 33.4%

 $[\alpha]_D^{24} = -10.3$ (*c* 1.65, CHCl₃)

Source of chirality: asymmetric hydrogenation

Absolute configuration: (S)

C₉H₁₂O₂


(S)-(-)-1-(2'-Methoxyphenyl)ethanol

Ee = 74.6%

 $[\alpha]_D^{24} = +38.6$ (*c* 1.13, CHCl₃)

Source of chirality: asymmetric hydrogenation

Absolute configuration: (R)

C₉H₁₂O₂


(R)-(+)-1-(4'-Methoxyphenyl)ethanol

Ee = 73.6%

 $[\alpha]_D^{24} = +27.5$ (neat)

Source of chirality: asymmetric hydrogenation

Absolute configuration: (R)

C₉H₉OF₃

(R)-(+)-1-(4'-Trifluoromethylphenyl)ethanol